AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26313454 — intervention group
Group type: COMPARATOR
Intervention: CEL (celecoxib 200 mg, once daily)
Number of subjects: 1219
Study 26313454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study 26313454 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID3
Number of subjects: 1219
Study 24144615 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 239
Study 24144615 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and Supportive Therapy (PST)
Number of subjects: 239
Study 21039402 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure with 6% skin area and 0.75 SED (7.5 mJ cm(‐2))
Number of subjects: 92
Study 21039402 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure with 12% skin area and 0.75 SED (7.5 mJ cm(‐2))
Number of subjects: 92
Study 21039402 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure with 0.75 SED (7.5 mJ cm(‐2))
Number of subjects: 92
Study 21039402 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure with 1.5 SED (15 mJ cm(‐2))
Number of subjects: 92
Study 21039402 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure with 3.0 SED (30 mJ cm(‐2))
Number of subjects: 92
Study 21039402 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall increase in 25(OH)D after irradiation
Number of subjects: 92
Study 18949961 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended high-frequency (EHF) audiometry
Number of subjects: 139
Study 18949961 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional audiometry
Number of subjects: 139
Study 18949961 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 139
Study 18949961 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF audiometry
Number of subjects: 139
Study 16753313 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress test
Number of subjects: 20
Study 16753313 — intervention group
Group type: COMPARATOR
Intervention: Non-stress condition
Number of subjects: 20
Study 12698181 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan 200 mg x m(‐2) on day 1 plus raltitrexed 3 mg x m(‐2) on day 2 (arm B)
Number of subjects: 38
Study 12698181 — intervention group
Group type: COMPARATOR
Intervention: raltitrexed 3 mg x m(‐2) on day 1 (arm A)
Number of subjects: 38
Study 12698181 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan plus raltitrexed
Number of subjects: 38
Study 10392322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (oral administration, once or twice daily for up to 28 days)
Number of subjects: 0
Study 10392322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (once-daily dosing)
Number of subjects: 0
Study 10392322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (twice-daily dosing)
Number of subjects: 0
Study 10392322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (oral administration)
Number of subjects: 0
Study 8694022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g ethyl ester daily)
Number of subjects: 25
Study 8694022 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (6 g ethyl ester daily)
Number of subjects: 25
Study 8694022 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (6 g ethyl ester daily)
Number of subjects: 25
Study 1687248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy with removal of the whole cystic duct
Number of subjects: 65
Study 1687248 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 65
Study 6682293 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laser photocoagulation
Number of subjects: 42
Study 6682293 — intervention group
Group type: COMPARATOR
Intervention: Indirect laser photocoagulation
Number of subjects: 42
Study 6682293 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 42
Study 6682293 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct photocoagulation
Number of subjects: 42
Study 31735408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 87
Study 31735408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Aerobic Training (IAT)
Number of subjects: 87
Study 31735408 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 87
Study 30290808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 317
Study 30290808 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 317
Study 27746565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 10mg ephedrine
Number of subjects: 100
Study 27746565 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid preloading with ringer lactate 15 mL.kg‐1
Number of subjects: 100
Study 24679996 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 21
Study 24679996 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21
Study 22397919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannheim Multicomponent Stress Test (MMST)
Number of subjects: 110
Study 20977501 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 19
Study 20977501 — intervention group
Group type: COMPARATOR
Intervention: CD4(+) CD25(+) T cell depletion
Number of subjects: 19
Study 20977501 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at 2nd month of life
Number of subjects: 19
Study 18179661 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day for 2 years
Number of subjects: 0
Study 18179661 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 0
Study 15731987 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin (1% creme rinse)
Number of subjects: 147
Study 15731987 — intervention group
Group type: COMPARATOR
Intervention: No exposure to known teratogenic drugs (control group)
Number of subjects: 147
Study 12637338 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin
Number of subjects: 123
Study 12637338 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin-niacin-antioxidant vitamins
Number of subjects: 123
Study 12637338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 123
Study 12637338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 10944479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg daily) for 26 days
Number of subjects: 0
Study 10944479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (15 mg daily) for 26 days
Number of subjects: 0
Study 10944479 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 days
Number of subjects: 0
Study 8814423 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability during sleep in patients with relapsing-remitting multiple sclerosis
Number of subjects: 20
Study 8814423 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to autonomic tests
Number of subjects: 20
Study 8814423 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance lesions correlation with cardiovascular sleep indexes
Number of subjects: 20
Study 1392793 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily for 12 weeks
Number of subjects: 112
Study 1392793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 4019949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (650 micrograms per puff, 2 puffs)
Number of subjects: 8
Study 4019949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31394155 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign EEG
Number of subjects: 161
Study 31394155 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant EEG
Number of subjects: 161
Study 31394155 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly malignant EEG
Number of subjects: 161
Study 31394155 — intervention group
Group type: COMPARATOR
Intervention: SSEP
Number of subjects: 161
Study 29984830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, thalidomide and dexamethasone (CTD)
Number of subjects: 0
Study 29984830 — intervention group
Group type: COMPARATOR
Intervention: Attenuated CTD
Number of subjects: 0
Study 29984830 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 26231819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) delivered via videoconference (VTC)
Number of subjects: 0
Study 26231819 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) delivered in person (IP)
Number of subjects: 0
Study 25264948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin (0.05 U/kg per hour)
Number of subjects: 50
Study 25264948 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose insulin (0.1 U/kg per hour)
Number of subjects: 50
Study 23372145 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (MIE; 50% Vo2peak for 60 min)
Number of subjects: 6
Study 23372145 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic high-intensity exercise (HIE; alternating 2 min at 25% and 2 min at 90% Vo2peak)
Number of subjects: 6
Study 23372145 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic high-intensity exercise (HIE)
Number of subjects: 6
Study 23372145 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (MIE)
Number of subjects: 6
Study 23372145 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 6
Study 20801010 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 31
Study 20801010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18077067 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic imitation of intransitive actions (hand opening and closing)
Number of subjects: 0
Study 18077067 — intervention group
Group type: COMPARATOR
Intervention: Control conditions with spatial compatibility variations
Number of subjects: 0
Study 16177446 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (5 pmol/min)
Number of subjects: 39
Study 16177446 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min)
Number of subjects: 39
Study 16177446 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-788 (1 nmol/min)
Number of subjects: 39
Study 16177446 — intervention group
Group type: COMPARATOR
Intervention: Mean plasma endothelin-1 levels
Number of subjects: 39
Study 12943027 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor change in dysfunctional attitudes
Number of subjects: 121
Study 12943027 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor change in extreme thinking
Number of subjects: 121
Study 10664826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) 50 micrograms intravenously
Number of subjects: 8
Study 10664826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 8863759 — intervention group
Group type: EXPERIMENTAL
Intervention: Running in water with a flotation device
Number of subjects: 8
Study 8863759 — intervention group
Group type: COMPARATOR
Intervention: Bicycle ergometry
Number of subjects: 8
Study 8863759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both water running and bicycle ergometry
Number of subjects: 8
Study 1355791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronactolol 30 mg
Number of subjects: 0
Study 1355791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronactolol 60 mg
Number of subjects: 0
Study 1355791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronactolol 120 mg
Number of subjects: 0
Study 3899672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 4 mg/day for 6 weeks
Number of subjects: 20
Study 3899672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphamethyldopa 250-750 mg/day for 6 weeks
Number of subjects: 20
Study 31145214 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine
Number of subjects: 0
Study 31145214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29425280 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood stunting
Number of subjects: 2193
Study 29425280 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood underweight
Number of subjects: 2193
Study 29425280 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood wasting by BMIAZ
Number of subjects: 2193
Study 29425280 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood wasting by MUACAZ
Number of subjects: 2193
Study 26879684 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight-Plus weight management programme (12-20 weeks low calorie diet replacement, food reintroduction, and long-term weight loss maintenance)
Number of subjects: 280
Study 26879684 — intervention group
Group type: COMPARATOR
Intervention: Usual guideline-based care
Number of subjects: 280
Study 25225424 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 to 4), granisetron (2 mg orally on days 1 to 4), and dexamethasone (4 mg orally on day 1 and 2 mg orally on days 2 to 3)
Number of subjects: 362
Study 25225424 — intervention group
Group type: COMPARATOR
Intervention: Placebo, granisetron (2 mg orally on days 1 to 4), and dexamethasone (8 mg orally on day 1 and 4 mg orally on days 2 to 3)
Number of subjects: 362
Study 22287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intermediate-dose cytarabine (mIDAC; Ara-C at a dose of 1.0 g/m(2) every 12 hours for 5 days)
Number of subjects: 26
Study 22287757 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (HDAC; Ara-C at a dose of 2.0 g/m(2) every 12 hours for 5 days)
Number of subjects: 26
Study 22287757 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (HDAC)
Number of subjects: 26
Study 22287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intermediate-dose cytarabine (mIDAC)
Number of subjects: 26
Study 20465831 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing counseling approach
Number of subjects: 272
Study 20465831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 272
Study 17660839 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 772
Study 17660839 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy or autologous transplantation
Number of subjects: 772
Study 18485530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition (cycling exercise)
Number of subjects: 12
Study 18485530 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition
Number of subjects: 12
Study 18485530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition
Number of subjects: 12
Study 15468717 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of proinflammatory cytokines (TNF‐alpha, IL‐1alpha, IL‐2, IL‐6, IL‐8) and increased production of autoimmune complexes
Number of subjects: 47
Study 15468717 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (angiotensin‐converting enzyme inhibitors, nitrates, diuretics, beta‐adrenoblockers; 27.6% received digoxin, disaggregatory agents)
Number of subjects: 47
Study 11158499 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP booster
Number of subjects: 3522
Study 11158499 — intervention group
Group type: COMPARATOR
Intervention: DT
Number of subjects: 3522
Study 9233865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily for 14 days)
Number of subjects: 140
Study 9233865 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 21 days)
Number of subjects: 140
Study 7956580 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 35
Study 3606073 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g immediately before vancomycin infusion, followed by 15 g at 2, 4, 6, and 8 hours)
Number of subjects: 6
Study 3606073 — intervention group
Group type: COMPARATOR
Intervention: Control (equal volume of water)
Number of subjects: 6
Study 31543378 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800mg/day
Number of subjects: 100
Study 31543378 — intervention group
Group type: COMPARATOR
Intervention: Control (statin therapy only)
Number of subjects: 100
Study 31151480 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback during treadmill training for 10 sessions over 5-6 weeks.
Number of subjects: 150
Study 31151480 — intervention group
Group type: COMPARATOR
Intervention: No feedback during treadmill training for 10 sessions over 5-6 weeks (Control).
Number of subjects: 150
Study 28178209 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberol® K (Berberis aristata, Silybum marianum and monacolin K and KA), once a day during dinner for 3 months
Number of subjects: 143
Study 28178209 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberol® K
Number of subjects: 143
Study 28178209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 25589237 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 20
Study 25589237 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 20
Study 24847155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 1123
Study 24847155 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting, permanent polymer stent (PP-EES)
Number of subjects: 1123
Study 24847155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES) in Cohort JR
Number of subjects: 1123
Study 24847155 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting, permanent polymer stent (PP-EES) in Cohort JR
Number of subjects: 1123
Study 23108814 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite technique of endoscopic DCR (using cautery, cold instrumentation, and laser)
Number of subjects: 30
Study 23108814 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic DCR
Number of subjects: 30
Study 19735400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 4 microg x kg(‐1) x min(‐1)
Number of subjects: 20
Study 19735400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 6 microg x kg(‐1) x min(‐1)
Number of subjects: 20
Study 16467562 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 0
Study 16467562 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Good response group (GRG) with <25% blasts in bone marrow within the first 2 weeks of treatment
Number of subjects: 42
Study 15801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor response group (PRG) with >25% blasts in bone marrow
Number of subjects: 42
Study 15801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin included in induction therapy
Number of subjects: 42
Study 15801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) in first complete remission (CR1)
Number of subjects: 42
Study 15801953 — intervention group
Group type: COMPARATOR
Intervention: Previous MRC UKALL XI trial
Number of subjects: 42
Study 11927701 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding during heel lance
Number of subjects: 30
Study 10235017 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for asymptomatic carotid artery disease with 60% or greater linear stenosis
Number of subjects: 0
Study 10235017 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for symptomatic carotid artery disease with 50% or greater linear stenosis
Number of subjects: 0
Study 10235017 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical recommendations
Number of subjects: 0
Study 7638370 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (H)
Number of subjects: 23
Study 7638370 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (M)
Number of subjects: 23
Study 7638370 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (H) and Methacholine (M)
Number of subjects: 23
Study 2652176 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 28
Study 2652176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no caffeine)
Number of subjects: 28
Study 786667 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg mephenoxalone
Number of subjects: 60
Study 786667 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg paracetamol
Number of subjects: 60
Study 786667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 400 mg mephenoxalone and 900 mg paracetamol
Number of subjects: 60
Study 30246570 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy
Number of subjects: 105
Study 30246570 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative writing
Number of subjects: 105
Study 30246570 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 30246570 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study 30095173 — intervention group
Group type: EXPERIMENTAL
Intervention: NPT and PDT
Number of subjects: 24
Study 30095173 — intervention group
Group type: COMPARATOR
Intervention: NPT only
Number of subjects: 24
Study 25530068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) plus oral morphine
Number of subjects: 40
Study 25530068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) plus oral morphine
Number of subjects: 40
Study 25781235 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide (120 mg three times a day)
Number of subjects: 85
Study 25781235 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose (50 mg three times a day)
Number of subjects: 85
Study 23254437 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine plus primaquine (30 mg/day for 14 days)
Number of subjects: 116
Study 23254437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus primaquine (30 mg/day for 14 days)
Number of subjects: 116